Zoetis Inc.

Zoetis Inc. is the world's largest animal health company, dedicated to nurturing the world and humankind by advancing care for animals. The company discovers, develops, manufactures, and commercializes a broad portfolio of medicines, vaccines, diagnostics, and technologies for both companion animals and livestock. Headquartered in Parsippany, New Jersey, U.S., Zoetis operates with a mission to improve animal health and welfare.

Its extensive product offerings include pharmaceuticals, vaccines, biologics, parasiticides, anti-infectives, and diagnostic instruments, with over 300 product lines. Zoetis serves a diverse market encompassing companion animals such as dogs, cats, and horses, as well as livestock including cattle, poultry, swine, fish, and sheep. The company emphasizes a 'Continuum of Care' approach, focusing on predicting, preventing, detecting, and treating animal diseases.

Under the leadership of CEO Kristin Peck, Zoetis maintains its position as the leading animal health company globally, with operations in over 100 countries. The company reported strong financial performance in 2025, with 6% organic operational revenue growth and 7% bottom-line growth, and anticipates moderate growth of 3% to 5% in 2026. Recent strategic moves include the acquisition of Neogen's animal genomics business in April 2026 to enhance its precision animal health capabilities, and a continued focus on long-acting innovations in areas like dermatology and pain management.